Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Substandard Thyroxin Drugs Raise Safety Concerns In Sri Lanka

This article was originally published in PharmAsia News

Executive Summary

Questions are being raised about transparency in Sri Lanka's handling of problem drugs in the wake of substandard thyroxin drugs reaching the market. Physicians are concerned the problems are not well-publicized or that substitute drugs can be questionable. Neither the thyroid pills behind the new concern nor their manufacturers were identified, although the drugs were said to have been imported by Sri Lanka's health system from India and the U.K., and that raw material had come from China and Germany. Some thyroxin has been withdrawn, others have been blacklisted, and the registration of others has been canceled. Physicians in private and state institutions have complained about the medicines. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts